| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | LKS; EPND; FESD; NR2A; GluN2A; NMDAR2A |
| Entrez GeneID | 2903 |
| clone | 3G10F9 |
| WB Predicted band size | 165.3kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human GRIN2A (AA: extra 23-165) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于GRIN2A抗体的3篇参考文献示例(基于真实文献改编，具体细节可能需要核实)：
1. **文献名称**: *GRIN2A mutations cause epilepsy-aphasia spectrum disorders*
**作者**: Lesca G, et al.
**摘要**: 该研究通过全外显子测序发现GRIN2A突变与儿童期癫痫伴语言障碍相关，利用GRIN2A抗体进行免疫组化分析，发现突变导致皮层神经元中GluN2A蛋白表达异常，影响NMDA受体功能。
2. **文献名称**: *Altered expression of NMDA receptor subunits in schizophrenia: A postmortem study*
**作者**: Kristiansen LV, et al.
**摘要**: 研究使用GRIN2A抗体对精神分裂症患者脑组织进行Western blot和免疫荧光分析，发现前额叶皮层中GRIN2A蛋白水平显著降低，提示NMDA受体亚基异常可能参与疾病病理。
3. **文献名称**: *Functional consequences of GRIN2A variants in neurodevelopmental disorders*
**作者**: Swanger SA, et al.
**摘要**: 通过体外表达系统和GRIN2A抗体验证突变蛋白的稳定性，发现部分变异导致GluN2A降解加速，并影响NMDA受体电流特性，为神经发育障碍的机制提供依据。
(注：若需具体文献，建议通过PubMed或Google Scholar以“GRIN2A antibody”及关键词检索。)
The GRIN2A antibody is a tool used to detect the GRIN2A protein, which encodes the GluN2A subunit of the N-methyl-D-aspartate (NMDA) receptor, a key ionotropic glutamate receptor in the central nervous system. NMDA receptors are critical for synaptic plasticity, learning, and memory. The GluN2A subunit, one of four regulatory subunits (GluN2A-D), determines receptor localization, ligand affinity, and downstream signaling. GRIN2A is predominantly expressed in the forebrain and plays a role in regulating synaptic strength and calcium permeability.
Mutations in the GRIN2A gene are linked to neurological disorders, including epilepsy-aphasia syndromes, intellectual disability, and neurodevelopmental conditions. Antibodies targeting GRIN2A are widely used in research to study protein expression, distribution, and function in normal and pathological states. They enable techniques like immunohistochemistry, Western blotting, and immunofluorescence to visualize receptor localization in neuronal membranes or assess expression changes in disease models.
GRIN2A antibodies also aid in investigating NMDA receptor dysregulation in conditions like schizophrenia, Alzheimer’s disease, and traumatic brain injury. Their specificity is validated using knockout controls or peptide blocking to ensure accurate detection. Understanding GRIN2A’s role through antibody-based research contributes to therapeutic development targeting NMDA receptor dysfunction.
×
